Table 3.
Analysis of time-to-treatment failure after the third dose of tozinameran.
| Covariate | Time-to-treatment failure | ||||
|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | ||||
| Median TTF (95% CI), months | HR (95% CI) | P value | HR (95% CI) | P value | |
| Treatment type - anti HER2 therapies - CDK4/6 inhibitors |
20.8 (17.2-NR) 14.2 (11.0-17.3) |
1.00 3.45 (1.54-7.73) |
0.003 |
1.00 2.57 (1.06-6.22) |
0.035 |
| Breakthrough infection - none - yes |
20.5 (12.7-28.3) 12.5 (6.1-18.8) |
1.00 1.69 (0.81-3.52) |
0.157 |
1.00 0.83 (0.34-2.05) |
0.696 |
| Antibody level
a
- high-responders - low-responders |
20.7 (16.2-NR) 14.7 (9.7-18.3) |
1.00 0.43 (0.21-0.88) |
0.020 |
1.00 0.76 (0.33-1.78) |
0.541 |
| T helper level
b
- high-responders - low-responders |
18.1 (16.5-NR) 12.2 (5.0-19.4) |
1.00 0.37 (0.18-0.74) |
0.006 |
1.00 0.53 (0.22-1.27) |
0.160 |
CI, confidence interval; HR, hazard ratio; CDK, cyclin-dependent kinase; HER2, epidermal growth factor receptor 2; NR, not reached.
a
low-responders indicate the subgroup of patients with an anti-RBD-S1 IgG titer <907 BAU/mL after the third dose of vaccine, high-responders indicates the subgroup of patients with an anti-RBD-S1 IgG titer ≥907 BAU/mL after the third dose of vaccine;
b
low-responders indicate the subgroup of patients with T helper cell count <806/µL after the third dose of tozinameran, high-responders indicate the subgroup of patients with NK cell count ≥806/µL after the third dose of tozinameran